title: Improved targeting and enhanced retention of the human, autologous, fibroblast-derived, induced, pluripotent stem cells to the sarcomeres of the infarcted myocardium with the aid of the bioengineered, heterospecific, tetravalent antibodies.
abstract: Clinical trials, to regenerate the human heart injured by myocardial infarction, involve the delivery of stem cells to the site of the injury. However, only a small fraction of the introduced stem cells are detected at the site of the injury, merely two weeks after this therapeutic intervention. This significantly hampers the effectiveness of the stem cell therapy. To resolve the aforementioned problem, we genetically and molecularly bioengineered heterospecific, tetravalent antibodies (htAbs), which have both exquisite specificity and high affinity towards human, pluripotent, stem cells through the htAbs' domains binding SSEA-4, SSEA-3, TRA-1-60, and TRA-1-81, as well as towards the injured cardiac muscle through the htAbs' domains binding human cardiac myosin, α-actinin, actin, and titin. The cardiac tissue was acquired from the patients, who were receiving heart transplants. The autologous, human, induced, pluripotent stem cells (hiPSCs) were generated from the patients' fibroblasts by non-viral delivery and transient expression of the DNA constructs for: Oct4, Nanog, Sox2, Lin28, Klf4, c-Myc. In the trials involving the htAbs, the human, induced, pluripotent stem cells anchored to the myocardial sarcomeres with the efficiency, statistically, significantly higher, than in the trials with non-specific or without antibodies (p < 0.0003). Moreover, application of the htAbs resulted in cross-linking of the sarcomeric proteins to create the stable scaffolds for anchoring of the stem cells. Thereafter, these human, induced pluripotent stem cells differentiated into cardiomyocytes at their anchorage sites. By bioengineering of these novel heterospecific, tetravalent antibodies and using them to guide and to anchor the stem cells specifically to the stabilized sarcomeric scaffolds, we demonstrated the proof of conceptin vitrofor improving effectiveness of regenerative therapy of myocardial infarction and created the foundations for the trialsin vivo.
authors: Phoenix Biomolecular Engineering Foundation, San Francisco, CA, USA.
authors: Marek
authors: M
authors: Malecki
keywords: Myocardial infarction; SSEA-3; SSEA-4; TRA-1-60; TRA-1-81; actin; bi-specific antibody; cardiac regeneration; desmin; heart attack; heterospecific tetravalent antibody; ischemic heart disease; myofibril; myosin; stem cell therapy; tetrabody; titin; troponin; α-actinin
references: Cytotherapy. 2013 Apr;15(4):399-415
references: 23294824
references: Stem Cells. 2007 Sep;25(9):2257-68
references: 17588935
references: J Appl Physiol (1985). 2008 Jun;104(6):1793-800
references: 18292296
references: J Vis Exp. 2011 Nov 03;(57):e3274
references: 22083019
references: Circ Res. 2009 Feb 27;104(4):e30-41
references: 19213953
references: Blood. 2011 Apr 7;117(14):e109-19
references: 21296996
references: Clin Res Cardiol. 2011 Oct;100(10):925-34
references: 21633921
references: Eur J Clin Invest. 1985 Dec;15(6):422-9
references: 3938414
references: Circulation. 2013 Jan 15;127(2):213-23
references: 23224061
references: Biomaterials. 2011 Feb;32(4):1102-9
references: 21035182
references: Science. 2007 Dec 21;318(5858):1917-20
references: 18029452
references: PLoS One. 2013;8(1):e53764
references: 23326500
references: Nature. 2008 May 22;453(7194):524-8
references: 18432194
references: J Am Coll Cardiol. 2009 Oct 20;54(17):1619-26
references: 19833262
references: J Clin Invest. 1976 Aug;58(2):439-46
references: 956377
references: Genes Dev. 2001 Feb 1;15(3):304-15
references: 11159911
references: Eur Heart J. 2010 Mar;31(6):691-702
references: 20022872
references: Circulation. 2009 Oct 13;120(15):1513-23
references: 19786631
references: Nature. 2008 Jan 10;451(7175):141-6
references: 18157115
references: Cell Res. 2011 Apr;21(4):579-87
references: 21102549
references: Trials. 2012 Jul 02;13:99
references: 22747980
references: Science. 2009 May 8;324(5928):797-801
references: 19325077
references: Macromol Biosci. 2013 Mar;13(3):366-75
references: 23335565
references: Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):213-8
references: 11756693
references: Blood. 2009 May 28;113(22):5476-9
references: 19299331
references: Stem Cell Rev Rep. 2009 Mar;5(1):72-80
references: 19184635
references: Stem Cells. 2007 Mar;25(3):712-7
references: 17138964
references: Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2883-8
references: 18287077
references: Tissue Eng Part A. 2012 Aug;18(15-16):1652-63
references: 22607369
references: Curr Cardiol Rev. 2011 Aug;7(3):201-12
references: 22758618
references: J Stem Cell Res Ther. 2013 Apr 2;3(1):
references: 23772337
references: PLoS One. 2011 Apr 08;6(4):e18293
references: 21494607
references: Circulation. 2003 Aug 19;108(7):863-8
references: 12900340
references: J Mol Cell Cardiol. 2012 Jun;52(6):1203-12
references: 22484618
references: Nat Biotechnol. 2008 Jul;26(7):795-7
references: 18568017
references: Tissue Eng Part A. 2010 Jun;16(6):2017-27
references: 20100033
references: J Cell Mol Med. 2011 Jun;15(6):1319-28
references: 20629987
references: J Stem Cell Res Ther. 2012 Nov 18;2(5):
references: 23293749
references: Eur Heart J. 2006 May;27(9):1114-22
references: 16510464
references: Am J Cardiol. 1984 Nov 1;54(8):964-70
references: 6496359
references: Stem Cells. 2008 Aug;26(8):1998-2005
references: 18511599
references: PLoS One. 2011 Feb 22;6(2):e16734
references: 21364991
references: Lancet. 2012 Mar 10;379(9819):895-904
references: 22336189
references: Cell. 2007 Nov 30;131(5):861-72
references: 18035408
references: JAMA. 2011 Nov 16;306(19):2110-9
references: 22084195
references: Circulation. 2007 Sep 11;116(11 Suppl):I38-45
references: 17846324
references: Cell Res. 2008 May;18(5):600-3
references: 18414447
references: Eur J Echocardiogr. 2010 Mar;11(2):165-71
references: 19946118
references: Circulation. 2005 Aug 30;112(9 Suppl):I150-6
references: 16159808
references: Stem Cells. 2010 Apr;28(4):765-74
references: 20178108